Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PFIZER INCPFE · Entity 2863 | Director | April 28, 2011 | April 28, 2011 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PFIZER INC
Report date April 28, 2011 · Filed April 28, 2011
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 97,679 |
Reported balance
After 2011-04-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2011-04-28 · Grant · Acquired 5,500 · Balance 97,679 F1: Each unit represents one phantom share of common stock. F2: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Each unit represents one phantom share of common stock.
F2: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
F3: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.
REGENERON PHARMACEUTICALS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,703 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 155 · Balance 1,703 F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $772.76 · Expires 2036-01-02 | Direct | 1,962 |
Reported balance
After 2026-01-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-02 · Grant · Acquired 1,962 · Balance 1,962 F3: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. |
| Common StockSEC Table I · non-derivative | Indirectby SLAT | 5,000 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,000 F2: These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 6,162 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 6,162 |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
F2: These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F3: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 30, 2022 Filed Mar 31, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 408 | $374.12 | $152,640.96 |
DisclosureSEC source: 0001708138-22-000030 · edgardoc.xml · nonDerivative · entry 3 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,522 | $0.00 Strike: $374.12 | $0.00 |
DisclosureSEC source: 0001708138-22-000030 · edgardoc.xml · derivative · entry 7 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,839 Underlying: Common Stock · 1,522 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,522 | $699.00 | $1,063,878.00 |
DisclosureSEC source: 0001708138-22-000030 · edgardoc.xml · nonDerivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,082 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,522 | $374.12 | $569,410.64 |
DisclosureSEC source: 0001708138-22-000030 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $608.68 | $304,340.00 |
DisclosureSEC source: 0001708138-22-000017 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 7,162 Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,707 | $0.00 Strike: $625.60 | $0.00 |
DisclosureSEC source: 0001708138-22-000005 · edgardoc.xml · derivative · entry 4 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,707 Underlying: Common Stock · 2,707 shares Expires 2032-01-03 F3 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 191 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-22-000005 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,082 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,612 | $0.00 Strike: $413.33 | $0.00 |
DisclosureSEC source: 0001708138-21-000082 · edgardoc.xml · derivative · entry 25 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,612 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,613 | $0.00 Strike: $413.33 | $0.00 |
DisclosureSEC source: 0001708138-21-000082 · edgardoc.xml · derivative · entry 24 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,612 Underlying: Common Stock · 3,613 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,479 | $0.00 Strike: $380.95 | $0.00 |
DisclosureSEC source: 0001708138-21-000082 · edgardoc.xml · derivative · entry 23 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,479 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 62 | $652.26 | $40,440.12 |
DisclosureSEC source: 0001708138-21-000082 · edgardoc.xml · nonDerivative · entry 20 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 891 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,712 | $651.10 | $2,416,883.20 |
DisclosureSEC source: 0001708138-21-000082 · edgardoc.xml · nonDerivative · entry 19 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 953 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 3,712 shares of Company stock on September 13, 2021 at prices ranging from $651.10 to $651.21. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,800 | $650.40 | $1,170,720.00 |
DisclosureSEC source: 0001708138-21-000082 · edgardoc.xml · nonDerivative · entry 18 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,665 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 1,800 shares of Company stock on September 13, 2021 at prices ranging from $650.19 to $650.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 838 | $649.46 | $544,247.48 |
DisclosureSEC source: 0001708138-21-000082 · edgardoc.xml · nonDerivative · entry 17 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,465 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 838 shares of Company stock on September 13, 2021 at prices ranging from $649.00 to $649.57. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 962 | $648.48 | $623,837.76 |
DisclosureSEC source: 0001708138-21-000082 · edgardoc.xml · nonDerivative · entry 16 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,303 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 962 shares of Company stock on September 13, 2021 at prices ranging from $648.30 to $648.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 151 | $647.58 | $97,784.58 |
DisclosureSEC source: 0001708138-21-000082 · edgardoc.xml · nonDerivative · entry 15 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,265 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 151 shares of Company stock on September 13, 2021 at prices ranging from $647.42 to $647.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $646.28 | $64,628.00 |
DisclosureSEC source: 0001708138-21-000082 · edgardoc.xml · nonDerivative · entry 14 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,416 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $645.66 | $64,566.00 |
DisclosureSEC source: 0001708138-21-000082 · edgardoc.xml · nonDerivative · entry 13 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,516 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $644.89 | $64,489.00 |
DisclosureSEC source: 0001708138-21-000082 · edgardoc.xml · nonDerivative · entry 12 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,616 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $643.49 | $64,349.00 |
DisclosureSEC source: 0001708138-21-000082 · edgardoc.xml · nonDerivative · entry 11 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,716 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 400 | $642.62 | $257,048.00 |
DisclosureSEC source: 0001708138-21-000082 · edgardoc.xml · nonDerivative · entry 10 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,816 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 400 shares of Company stock on September 13, 2021 at prices ranging from $642.36 to $642.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $641.12 | $64,112.00 |
DisclosureSEC source: 0001708138-21-000082 · edgardoc.xml · nonDerivative · entry 9 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,216 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $640.77 | $64,077.00 |
DisclosureSEC source: 0001708138-21-000082 · edgardoc.xml · nonDerivative · entry 8 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,316 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 203 | $639.20 | $129,757.60 |
DisclosureSEC source: 0001708138-21-000082 · edgardoc.xml · nonDerivative · entry 7 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,416 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 203 shares of Company stock on September 13, 2021 at prices ranging from $639.09 to $639.32. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 676 | $638.64 | $431,720.64 |
DisclosureSEC source: 0001708138-21-000082 · edgardoc.xml · nonDerivative · entry 6 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,619 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 676 shares of Company stock on September 13, 2021 at prices ranging from $638.16 to $638.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $637.29 | $127,458.00 |
DisclosureSEC source: 0001708138-21-000082 · edgardoc.xml · nonDerivative · entry 5 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,295 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on September 13, 2021 at prices ranging from $637.20 to $637.37. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $636.74 | $63,674.00 |
DisclosureSEC source: 0001708138-21-000082 · edgardoc.xml · nonDerivative · entry 4 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,495 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,612 | $413.33 | $1,492,947.96 |
DisclosureSEC source: 0001708138-21-000082 · edgardoc.xml · nonDerivative · entry 3 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,613 | $413.33 | $1,493,361.29 |
DisclosureSEC source: 0001708138-21-000082 · edgardoc.xml · nonDerivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,983 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,479 | $380.95 | $944,375.05 |
DisclosureSEC source: 0001708138-21-000082 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,687 | $612.38 | $1,033,085.06 |
DisclosureSEC source: 0001237899-21-000012 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 7,662 Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,084 | $0.00 Strike: $371.40 | $0.00 |
DisclosureSEC source: 0001708138-21-000028 · edgardoc.xml · derivative · entry 5 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,084 shares Expires 2029-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,084 | $549.00 | $1,144,116.00 |
DisclosureSEC source: 0001708138-21-000028 · edgardoc.xml · nonDerivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 891 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,084 | $371.40 | $773,997.60 |
DisclosureSEC source: 0001708138-21-000028 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,700 | $0.00 Strike: $371.40 | $0.00 |
DisclosureSEC source: 0001708138-21-000023 · edgardoc.xml · derivative · entry 5 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,084 Underlying: Common Stock · 1,700 shares Expires 2029-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,700 | $525.00 | $892,500.00 |
DisclosureSEC source: 0001708138-21-000023 · edgardoc.xml · nonDerivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 891 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,700 | $371.40 | $631,380.00 |
DisclosureSEC source: 0001708138-21-000023 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,480 | $0.00 Strike: $380.95 | $0.00 |
DisclosureSEC source: 0001708138-21-000012 · edgardoc.xml · derivative · entry 5 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,479 Underlying: Common Stock · 2,480 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,480 | $554.32 | $1,374,713.60 |
DisclosureSEC source: 0001708138-21-000012 · edgardoc.xml · nonDerivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 891 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,480 | $380.95 | $944,756.00 |
DisclosureSEC source: 0001708138-21-000012 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:53 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,613 | $0.00 Strike: $482.68 | $0.00 |
DisclosureSEC source: 0001237899-21-000004 · edgardoc.xml · derivative · entry 4 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,613 Underlying: Common Stock · 3,613 shares Expires 2031-01-04 F3 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:53 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 248 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-21-000004 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 891 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| September 22, 2020 Filed Sep 23, 2020 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,480 | $0.00 Strike: $380.95 | $0.00 |
DisclosureSEC source: 0001708138-20-000106 · edgardoc.xml · derivative · entry 8 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,959 Underlying: Common Stock · 2,480 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 22, 2020 Filed Sep 23, 2020 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,610 | $0.00 Strike: $376.69 | $0.00 |
DisclosureSEC source: 0001708138-20-000106 · edgardoc.xml · derivative · entry 7 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,610 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 22, 2020 Filed Sep 23, 2020 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $552.36 | $552,360.00 |
DisclosureSEC source: 0001708138-20-000106 · edgardoc.xml · nonDerivative · entry 5 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 9,349 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 22, 2020 Filed Sep 23, 2020 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5,090 | $552.36 | $2,811,512.40 |
DisclosureSEC source: 0001708138-20-000106 · edgardoc.xml · nonDerivative · entry 3 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 22, 2020 Filed Sep 23, 2020 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,610 | $376.69 | $983,160.90 |
DisclosureSEC source: 0001708138-20-000106 · edgardoc.xml · nonDerivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,733 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 22, 2020 Filed Sep 23, 2020 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,480 | $380.95 | $944,756.00 |
DisclosureSEC source: 0001708138-20-000106 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,123 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,613 | $0.00 Strike: $413.33 | $0.00 |
DisclosureSEC source: 0001708138-20-000082 · edgardoc.xml · derivative · entry 16 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,225 Underlying: Common Stock · 3,613 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 400 | $612.29 | $244,916.00 |
DisclosureSEC source: 0001708138-20-000082 · edgardoc.xml · nonDerivative · entry 13 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 400 shares of Company stock on July 1, 2020 at prices ranging from $612.21 to $612.35. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2020 at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.